TherapeuticsMD Inc is a biotechnology company focused on developing and commercializing innovative women's health products
The company aims to address unmet medical needs through its extensive portfolio of hormonal therapies and other innovative treatments designed specifically for women. By leveraging advanced scientific research and clinical development, TherapeuticsMD seeks to improve the quality of life for women experiencing various health conditions, including menopausal symptoms and reproductive health challenges. Their commitment to women's health is reflected in their ongoing efforts to bring new and effective therapies to market.
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQTXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarter ended September 30, 2024.
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQTXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter ended June 30, 2024.
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQTXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2024.
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQTXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023.
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQTXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarter ended September 30, 2023.
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Tuesday The Dow traded up 0.19% to 34,159.14 while the NASDAQ rose 0.84% to 13,631.99. The S&P 500 also rose, gaining, 0.30% to 4,379.06.
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQTXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter ended June 30, 2023.
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQTXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2023.
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQTXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2022.
TherapeuticsMD, Inc. (NASDAQTXMD) (“TherapeuticsMD,” “TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced that it has completed its previously announced transaction with Mayne Pharma Group Limited (“Mayne Pharma”), an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals, pursuant to which TXMD granted Mayne Pharma an exclusive license to commercialize TXMD’s products in the United States. In addition, TXMD sold certain assets to Mayne Pharma to enable it to commercialize the products.
TherapeuticsMD, Inc. (NASDAQTXMD) (“TherapeuticsMD,” “TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced that it has entered into definitive agreements to license its products to an affiliate of Mayne Pharma Group Limited (“Mayne Pharma”), an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals, for commercialization in the United States. In addition, TXMD has agreed to sell certain assets to Mayne Pharma to allow Mayne Pharma to commercialize the products.
TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQTXMD), an innovative, leading women’s healthcare company, today reported financial results for the third quarter ended September 30, 2022.
